Associated Genetic Biomarkers
RBBP8 is altered in 2.56% of all cancers with colon adenocarcinoma, lung adenocarcinoma, melanoma, glioblastoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in RBBP8 are RBBP8 Mutation (0.35%), RBBP8 Amplification (0.03%), RBBP8 K357Nfs*3 (0.03%), RBBP8 V329I (0.01%), and RBBP8 H358Tfs*8 (0.01%) .
RBBP8 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains RBBP8 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with RBBP8 status in the inclusion eligibility criteria most commonly target urothelial carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is RBBP8 Mutation .
Olaparib is the most frequent therapy in trials with RBBP8 as an inclusion criteria .
Significance of RBBP8 in Diseases
Urothelial Carcinoma +
RBBP8 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RBBP8 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.